Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01282424 · OUTCOME

Study Drug Exposure

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas · Source last updated 2019-07-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
months
Interval / dispersion
Standard Deviation
Time frame
Start of Treatment to End of Treatment (up to 81 months)

What was measured

The average idelalisib exposure was summarized.

Analysis population: Participants in the ITT Analysis Set were analyzed.

Groups in this outcome

Idelalisib

Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Idelalisib125

Reported measurements

Source class 1
Values in months · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Idelalisib13.215.08Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        15.08
        value
        13.2
denoms
  1. counts
    1. group Id
      OG000
      value
      125
    units
    Participants
description
The average idelalisib exposure was summarized.
dispersion Type
Standard Deviation
groups
  1. description
    Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.
    id
    OG000
    title
    Idelalisib
param Type
MEAN
population Description
Participants in the ITT Analysis Set were analyzed.
reporting Status
POSTED
time Frame
Start of Treatment to End of Treatment (up to 81 months)
title
Study Drug Exposure
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice